Use of darbepoetin alfa for myelodysplastic syndrome coincident with chronic kidney disease.
作者信息
Nagai Kei, Yamagata Kunihiro
机构信息
Department of Nephrology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
出版信息
CEN Case Rep. 2016 May;5(1):117-118. doi: 10.1007/s13730-016-0212-7. Epub 2016 Jan 22.
Abstract
摘要
相似文献
1
Use of darbepoetin alfa for myelodysplastic syndrome coincident with chronic kidney disease.
CEN Case Rep. 2016 May;5(1):117-118. doi: 10.1007/s13730-016-0212-7. Epub 2016 Jan 22.
2
Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
Pharmacotherapy. 2007 Mar;27(3):434-46. doi: 10.1592/phco.27.3.434.
3
A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
J Support Oncol. 2005 Nov-Dec;3(6):419-26.
4
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.
5
Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
Am J Nephrol. 2004 Jul-Aug;24(4):453-60. doi: 10.1159/000080452. Epub 2004 Aug 25.
6
A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
Curr Med Res Opin. 2008 Aug;24(8):2181-7. doi: 10.1185/03007990802240552. Epub 2008 Jun 18.
7
An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
J Intern Med. 2006 Dec;260(6):577-85. doi: 10.1111/j.1365-2796.2006.01723.x.
8
Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.
Pediatr Nephrol. 2002 Nov;17(11):933-7. doi: 10.1007/s00467-002-0932-0. Epub 2002 Sep 14.
9
Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Am J Nephrol. 2006;26(2):149-56. doi: 10.1159/000092852. Epub 2006 Apr 21.
10
Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
J Clin Pharmacol. 2010 Sep;50(9 Suppl):75S-90S. doi: 10.1177/0091270010377201.
引用本文的文献
1
Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report.
J Med Case Rep. 2017 Oct 19;11(1):296. doi: 10.1186/s13256-017-1468-z.
本文引用的文献
1
Chapter 3: Use of ESAs and other agents to treat anemia in CKD.
Kidney Int Suppl (2011). 2012 Aug;2(4):299-310. doi: 10.1038/kisup.2012.35.
2
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Ann Intern Med. 2010 Jul 6;153(1):23-33. doi: 10.7326/0003-4819-153-1-201007060-00252. Epub 2010 Jun 24.
3
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.
Br J Haematol. 2003 Jan;120(2):187-200. doi: 10.1046/j.1365-2141.2003.03907.x.
4
Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.
Nephron. 1997;77(2):176-85. doi: 10.1159/000190270.
Zotero 插件